Rahul Aggarwal, Susan Halabi, William Kevin Kelly, Daniel George, John F. Mahoney, Frederick Millard, Walter M. Stadler, Michael J. Morris, Philip Kantoff, J. Paul Monk, Michael Carducci, Eric J. Small and for the Alliance for Clinical Trials in Oncology The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer Cancer 119
A retrospective analysis of patients with metastatic, castrate-resistant prostate cancer who receive docetaxel-based chemotherapy on a randomized phase 3 clinical trial (CALGB 90401) does not provide evidence of an adverse impact of prior androgen synthesis inhibition with ketoconazole on subsequent clinical outcomes, contrary to preliminary evidence of cross-resistance between these modalities of therapy. The study results may have implications for the sequencing of novel androgen synthesis inhibitors and taxane-based chemotherapy, highlighting the need for prospective, randomized clinical trials to define the optimal sequence of therapy for metastatic, castration-resistant prostate cancer.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf